ES2422171T3 - Antígenos de carbunco y procedimientos de uso - Google Patents

Antígenos de carbunco y procedimientos de uso

Info

Publication number
ES2422171T3
ES2422171T3 ES05758632T ES05758632T ES2422171T3 ES 2422171 T3 ES2422171 T3 ES 2422171T3 ES 05758632 T ES05758632 T ES 05758632T ES 05758632 T ES05758632 T ES 05758632T ES 2422171 T3 ES2422171 T3 ES 2422171T3
Authority
ES
Spain
Prior art keywords
anthrax
subject
immune response
use procedures
anthrax antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05758632T
Other languages
English (en)
Inventor
Susan Wimer-Mackin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Montana Inc
Original Assignee
Takeda Vaccines Montana Inc
Ligocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Montana Inc, Ligocyte Pharmaceuticals Inc filed Critical Takeda Vaccines Montana Inc
Application granted granted Critical
Publication of ES2422171T3 publication Critical patent/ES2422171T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición en polvo seco adecuada para inducir una respuesta inmunitaria para el carbunco en un sujetocuando se administra a una superficie mucosa del sujeto, que comprende antígeno protector (PA) o un fragmentoinmunógeno del mismo y monofosforil lípido A (MPL), en la que parte del PA está presente como un péptidoconjugado con un péptido poli(ácido g-D-glutámico) (PGA), y en la que la respuesta inmunitaria puede mejorar oevitar al menos un síntoma de la enfermedad del carbunco.
ES05758632T 2004-02-11 2005-02-11 Antígenos de carbunco y procedimientos de uso Expired - Lifetime ES2422171T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54413004P 2004-02-11 2004-02-11
US54484804P 2004-02-12 2004-02-12
PCT/US2005/004678 WO2005086637A2 (en) 2004-02-11 2005-02-11 Anthrax antigens and methods of use

Publications (1)

Publication Number Publication Date
ES2422171T3 true ES2422171T3 (es) 2013-09-09

Family

ID=34976060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05758632T Expired - Lifetime ES2422171T3 (es) 2004-02-11 2005-02-11 Antígenos de carbunco y procedimientos de uso

Country Status (4)

Country Link
US (1) US8409590B2 (es)
EP (1) EP1735338B1 (es)
ES (1) ES2422171T3 (es)
WO (1) WO2005086637A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318376A1 (en) * 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
WO2012147084A2 (en) * 2011-04-26 2012-11-01 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders
WO2013022808A2 (en) * 2011-08-05 2013-02-14 The University Of Chicago Immunogenic protein conjugates and methods for making and using the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172126A (en) 1976-11-08 1979-10-23 Sankyo Company Limited Method for the inactivation of microbial toxins and attenuation of vaccines
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
RU1566532C (ru) 1988-03-24 1995-12-20 Всесоюзный государственный научно-контрольный институт ветпрепаратов Способ изготовления вакцины против сибирской язвы животных
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2115433C1 (ru) 1992-08-28 1998-07-20 Научно-исследовательский институт микробиологии МО РФ Вакцина сибиреязвенная комбинированная
RU2056861C1 (ru) 1993-04-23 1996-03-27 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Ассоциированная вакцина против сибирской язвы и ящура и способ профилактики сибирской язвы и ящура
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6316006B1 (en) * 1994-11-23 2001-11-13 The United States Of America As Represented By The Secretary Of The Army Asporogenic B anthracis expression system
RU2112544C1 (ru) 1994-12-27 1998-06-10 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Вакцина против сибирской язвы и эмфизематозного карбункула живая ассоциированная и способ профилактики этих заболеваний
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
RU2095409C1 (ru) 1995-06-27 1997-11-10 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Способ изготовления вакцины против сибирской язвы животных
RU2123532C1 (ru) 1995-11-21 1998-12-20 Ставропольский научно-исследовательский противочумный институт Способ отбора культур сибиреязвенных вакцинных штаммов и изготовленных из них вакцин
US6592872B1 (en) 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
RU2142010C1 (ru) 1997-09-15 1999-11-27 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ глубинного культивирования сибиреязвенного вакцинного штамма сти-1
RU2142009C1 (ru) 1997-09-15 1999-11-27 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ поддержания сибиреязвенного вакцинного штамма сти-1
RU2141340C1 (ru) 1998-04-21 1999-11-20 Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии Ассоциированная вакцина против сибирской язвы, анаэробной дизентерии и инфекционной энтеротоксемии овец и способ профилактики этих болезней
RU2151798C1 (ru) 1998-06-24 2000-06-27 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ концентрирования споровых культур в производстве сибиреязвенных вакцинных препаратов
US6770479B1 (en) 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
US6329156B1 (en) 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
RU2181294C2 (ru) 1999-08-11 2002-04-20 Научно-исследовательский институт микробиологии МО РФ Способ получения сухой комбинированной сибиреязвенной вакцины
FR2798291B1 (fr) 1999-09-10 2005-01-14 Pasteur Institut Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2398207A1 (en) * 1999-12-22 2001-06-28 The Ohio State University Research Foundation Methods for protecting against lethal infection with bacillus anthracis
RU2181296C2 (ru) 2000-07-13 2002-04-20 ВНИИ ветеринарной вирусологии и микробиологии Ассоциированная вакцина против сибирской язвы и оспы овец
JP4331940B2 (ja) * 2001-01-12 2009-09-16 ベクトン・ディキンソン・アンド・カンパニー 薬物の呼吸器用送出装置、カートリッジ、および、その製造方法
RU2198921C2 (ru) 2001-03-06 2003-02-20 Центр военно-технических проблем биологической защиты Научно-исследовательского института микробиологии Министерства обороны Российской Федерации Способ получения нативной споровой суспензии для приготовления сибиреязвенных вакцин
RU2180917C1 (ru) 2001-05-21 2002-03-27 Федеральное государственное учреждение Российский научно-исследовательский противочумный институт "Микроб" Штамм bacillus anthracis km90 - основа для генетического конструирования продуцентов сибиреязвенных антигенов
WO2003049670A2 (en) 2001-07-27 2003-06-19 Immuno-Rx, Inc. Adjuvant formulations for bacterial and virus vaccines and method of making same
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
RU2191599C1 (ru) 2001-11-01 2002-10-27 Караваев Юрий Дмитриевич Ассоциированная вакцина для профилактики сибирской язвы и некробактериоза животных
WO2003048390A1 (en) 2001-12-05 2003-06-12 Rakesh Bhatnagar A process for the preparation of a non-toxic anthrax vaccine
US20030118591A1 (en) 2001-12-21 2003-06-26 Joshua Levy Passive hyperimmune antibody therapy in the treatment of anthrax
US7354760B2 (en) * 2001-12-26 2008-04-08 University Of Central Florida Research Foundation, Inc. Expression of protective antigens in transgenic chloroplasts
US20040013688A1 (en) 2002-07-03 2004-01-22 Cambridge Scientific, Inc. Vaccines to induce mucosal immunity
AU2003255275A1 (en) 2003-02-13 2004-09-09 Becton, Dickinson And Company Improved anthrax vaccines and delivery methods
WO2005007804A2 (en) 2003-04-10 2005-01-27 President And Fellows Of Harvard College Anthrax conjugate vaccine and antibodies
WO2005000884A1 (en) 2003-06-05 2005-01-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
US20070148188A1 (en) 2003-07-30 2007-06-28 Merck & Co., Inc. Anthrax vaccine
GB0401036D0 (en) 2004-01-17 2004-02-18 Royal Holloway University Of L Improvements in or relating to vaccination

Also Published As

Publication number Publication date
US8409590B2 (en) 2013-04-02
US20070202130A1 (en) 2007-08-30
EP1735338A4 (en) 2008-04-16
EP1735338A2 (en) 2006-12-27
WO2005086637A2 (en) 2005-09-22
WO2005086637A3 (en) 2006-12-28
EP1735338B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
Peek et al. Nanotechnology in vaccine delivery
ATE507840T1 (de) Hilfszusammensetzung für vakzinen, die über die schleimhaut oder durch injektion verabreicht werden
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
CR10101A (es) Nueva composición
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AR059203A1 (es) Composiciones para uso vaginal
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
AR025750A1 (es) Vacunas
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
BRPI0510430A (pt) composições e métodos para vacinação mucosal
MX2009008577A (es) Prevencion y tratamiento contra la enfermedad asociada a arcovirus porcion sub-clinica.
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR060580A1 (es) Elastomeros de silicona que contienen antisepticos
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
DK1259259T3 (da) Mucosal adjuvansformulering
SG178904A1 (en) Combination vaccines against respiratory tract diseases
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
PH12017501257A1 (en) Foot-and-mouth disease vaccine
AR088907A1 (es) Vacuna
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
ES2422171T3 (es) Antígenos de carbunco y procedimientos de uso
WO2006076587A3 (en) Peptides for delivery of mucosal vaccines